A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510021-16-00

Acronym

AFM28-101

Enrollment

Registered

2024-10-08

Start date

2023-03-08

Completion date

2025-06-11

Last updated

2025-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory/relapsed (R/R) CD123-positive acute myeloid leukemia (AML)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026